Navigation Links
Quest Diagnostics Successfully Completes Acquisition of Celera
Date:5/17/2011

MADISON, N.J., May 17, 2011 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today the successful completion of its acquisition of Celera Corporation (NASDAQ: CRA).  The acquisition was completed by means of a short-form merger under Delaware law, under which a wholly owned subsidiary of Quest Diagnostics was merged with and into Celera, with Celera surviving the merger as a wholly owned subsidiary of Quest Diagnostics.  As a result of the merger, each share of Celera common stock (other than shares held by Celera, Quest Diagnostics or any of their respective affiliates, or shares held by stockholders that properly exercise appraisal rights under Delaware law) was converted into the right to receive the same $8 in cash, without interest and less any withholding of taxes, that was paid in the tender offer for all outstanding shares of Celera common stock, which expired on May 10.

Also, as a result of the merger, Celera shares ceased to be traded on the NASDAQ Global Select Market and Celera will no longer have reporting obligations under the Securities Exchange Act of 1934, as amended.

Holders of Celera shares of common stock that did not tender their shares into the tender offer will receive by mail written instructions for surrendering their share certificates or transferring their book-entry shares, including a letter of transmittal, and information regarding the exercise of appraisal rights under Delaware law.

About Quest Diagnostics

Quest Diagnostics is the world's leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions.  The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and
'/>"/>

SOURCE Quest Diagnostics Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Quest Diagnostics Declares Quarterly Cash Dividend
2. Questcor Discusses ISS Proxy Recommendations; Provides Business Update
3. Quest Diagnostics Announces Completion of Final Extension of the Subsequent Offering Period and Intent to Exercise Top-Up Option and Complete Merger
4. Quest Diagnostics Sponsors American Cancer Societys Choose You® Movement
5. Quest Diagnostics Announces Final Extension of Subsequent Offering Period for Shares of Celera
6. Cell Therapeutics Announces Planned Reverse Stock Split; Receives NASDAQ Notice of Non-Compliance; Intends to Request Hearing
7. Quest Diagnostics Launches Simplexa™ C. Difficile Universal Direct Test in Europe
8. Quest Diagnostics Announces One Day Extension of Offer to Acquire Celera to 5pm Today
9. Patient Advocates File FOIA Request to FDA on Avastin
10. Shareholders to Challenge Johnson & Johnsons Support for Left-Wing Policy Agenda: CEO William C. Weldon to Be Questioned on Firms Failure to Disclose Financial Information on Firms ObamaCare Lobbying It Pledged to Release Last Year
11. HemaQuest Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Study of HQK-1001 in Patients With Sickle Cell Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... and Markets ( http://www.researchandmarkets.com/research/5hkm2f/medical_oxygen ) has announced ... Global Strategic Business Report" report to their offering. ... Medical Oxygen Systems in US$ Thousands by the following ... Regulators, and Oxygen Conserving Devices. The report provides separate ... , Japan , Europe ...
(Date:4/17/2015)... DULLES, Va. , April 17, 2015 ... and distribution of radiopharmaceuticals, announced today that it has ... IBA Molecular North America, Inc. (IBAM NA), to Illinois Health ... continue to operate as an independent company headquartered in ... well positioned to take advantage of new product and ...
(Date:4/17/2015)... TWi Pharmaceuticals, Inc. ("TWi", Stock Ticker:4180.TT) today ... USA , has obtained state sales licenses from ... been in close contact with the major nationwide retail ... own label specialty generic products sold through these nationwide ... According to IMS Health, the U.S. pharma ...
Breaking Medicine Technology:Medical Oxygen Systems - 2015 Global Strategic Business Report Featuring Leading Players, Caire, Invacare & Philips Respironics 2Health Care System to Acquire IBA Molecular North America 2Health Care System to Acquire IBA Molecular North America 3
... of Bavituximab in ... Carboplatin and Paclitaxel-, TUSTIN, Calif., Jan. 22 ... biopharmaceutical,company developing monoclonal antibodies for the treatment of cancer ... Phase II,clinical protocol to study bavituximab in combination with ...
... II Investigational Trial Published in CANCER: the Journal of the ... ... Cell Therapeutics, Inc.,(CTI) (Nasdaq: CTIC ; MTAX) announced ... the journal CANCER demonstrate that the,addition of radioimmunotherapy (RIT) to ...
Cached Medicine Technology:Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer 2Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer 3Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer 4Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent 2Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent 3Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent 4Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent 5
(Date:4/18/2015)... April 18, 2015 On April 14th, 2015, ... Report , which they say, “exposes a tactical shift by ... malware variants were introduced in 2014 - almost a million ... Day threats to be identified and patched by prominent manufacturers ... clear that doing business in a digital world can be ...
(Date:4/18/2015)... 18, 2015 “ ArcAngel ” was featured ... a look at the latest and coolest applications ... the host of AppWatch and technology expert, conducted the app ... safety app. , In a turbulent world, people may ... 911 should always be their first move, but some situations ...
(Date:4/18/2015)... French physician and gastronome Anthelme Brillat-Savarin understood the ... “Tell me what you eat, and I will tell ... stress or sadness has often been attributed to women, ... collected from their Emotional Eating Test reveals ... for different reasons. , Collecting data from 521 emotional ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 John Evans, ... Party on the Patio from 2 p.m. to 3 ... located at 1320 Executive Ct. in Pekin, Illinois, serves ... who need some help to maintain their independence. , ... and tropical treats will be served during the luau. ...
(Date:4/17/2015)... April 17, 2015 ERGO-Pedic Products, LLC, ... introducing two new products to help a broader range ... pain relief are the second most common visitors to ... product, designed specifically to help relieve sitting pain. Then, ... and thousands of happy customers later, we began getting ...
Breaking Medicine News(10 mins):Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 3Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 4Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 5Health News:A Personal Safety Application was Featured on NewsWatch Television 2Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 2Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 3Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 4Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 5Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 6Health News:John Evans Supportive Living Community Prepares for Party on the Patio 2Health News:Seat Cushion Company Credits Customer Driven Design For Two New Products 2
... with 21 pens of cattle in commercial feedlots ... Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian ... a large-scale commercial beef feedlot study with the ... have been published in this month,s issue of ...
... Tens of Thousands of Americans Die Unnecessarily Every Year From Preventable ... ... 13, 2009 -- In support of National Patient Safety Awareness ... and compliance solutions for the healthcare industry, has produced an educational ...
... Cirangle, the most experienced bariatric surgeon in the state of Hawaii is ... the outer islands, Dr. Cirangle,s weight loss surgery patients will now have ... ... (PRWEB) March 13, 2009 -- As America,s fight with obesity continues, it ...
... Center for Refugee Health and Human Rights (BCRHHR) ... the large number of Tibetan refugee monks who ... Boston suffering from symptoms of traumatic stress, interfering ... by their traditional healers as having srog-rLung, a ...
... severely limit the movement of your pet, especially in the winter. ... industry in supplying the best medications to treat arthritis and joint pain ... ... leading online veterinary pharmacy and supplier of pet meds , announced ...
... National Association of Boards of Pharmacy(R) (NABP(R)) is one ... of Excellence in the first round of the 2009 ... sponsored by the American Society of Association Executives (ASAE) ... in Mount Prospect, IL, received the award for its ...
Cached Medicine News:Health News:Econiche(TM) Vaccine Shows 92% Reduction in Colonization of E. coli O157 in Vaccinated Cattle 2Health News:Econiche(TM) Vaccine Shows 92% Reduction in Colonization of E. coli O157 in Vaccinated Cattle 3Health News:Econiche(TM) Vaccine Shows 92% Reduction in Colonization of E. coli O157 in Vaccinated Cattle 4Health News:Econiche(TM) Vaccine Shows 92% Reduction in Colonization of E. coli O157 in Vaccinated Cattle 5Health News:Econiche(TM) Vaccine Shows 92% Reduction in Colonization of E. coli O157 in Vaccinated Cattle 6Health News:Quantros Produces Video Detailing Enormous Problem of Preventable Medical Errors Plaguing The U.S. Healthcare System 2Health News:Quantros Produces Video Detailing Enormous Problem of Preventable Medical Errors Plaguing The U.S. Healthcare System 3Health News:Hawaii's Most Experienced and Only Fellowship-Trained Weight Loss Surgeon Now Coming to Hilo 2Health News:Hawaii's Most Experienced and Only Fellowship-Trained Weight Loss Surgeon Now Coming to Hilo 3Health News:Researchers discover ways of integrating treatment of traumatized Tibetan refugee monks 2Health News:Researchers discover ways of integrating treatment of traumatized Tibetan refugee monks 3Health News:PetCareRx Reinforces its Range of Arthritis and Joint Care Products for Winter 2Health News:NABP Wins ASAE's 2009 Associations Advance America Award of Excellence 2Health News:NABP Wins ASAE's 2009 Associations Advance America Award of Excellence 3
... is a handheld, noninvasive ultrasound instrument that ... operate, so any staff member can scan ... images from exams and print BVI 6100 ... just log on to ScanPoint®, Diagnostic Ultrasound's ...
... The Mobile BladderScan® BVI 6400 calculates ... ultrasound technology. V-MODE® ultrasound is accurate, ... seconds, the BladderScan® measures ultrasonic reflections ... planes, creates a 3-dimensional image of ...
... EXP Injectable Bulking Agent is ... suspended in a water-based carrier ... Agent is indicated for the ... stress urinary incontinence due to ...
... The MIS is designed to ... in the area of the mid-urethra. ... 30 minutes, and can be performed ... department which allows the patient to ...
Medicine Products: